SMMT Summit Therapeutics Inc
Price (delayed)
$23.465
Market cap
$17.31B
P/E Ratio
N/A
Dividend/share
N/A
EPS
$0
Enterprise value
$17.21B
Summit Therapeutics, empowered by its Discuva Platform, the Company's innovative antibiotic discovery engine, led by Dr. Ventzislav Stefanov and supported by BARDA and Carb-X funding, intends to be the leader
Highlights
The EPS has soared by 100% YoY
The debt has dropped by 93% year-on-year and by 78% since the previous quarter
The net income has soared by 64% YoY but it has contracted by 13% from the previous quarter
SMMT's equity is down by 11% since the previous quarter
Key stats
What are the main financial stats of SMMT
Market
Valuations
Earnings
Shares outstanding
737.68M
Market cap
$17.31B
Enterprise value
$17.21B
Price to earnings (P/E)
N/A
Price to book (P/B)
44.51
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$226M
Net income
-$221.32M
EBIT
-$212.63M
EBITDA
-$212.54M
Free cash flow
-$142.25M
Per share
Balance sheet
Liquidity
EPS
$0
EPS diluted
$0
Free cash flow per share
-$0.2
Book value per share
$0.53
Revenue per share
$0
TBVPS
$0.6
Total assets
$435.56M
Total liabilities
$46.81M
Debt
$7.22M
Equity
$388.75M
Working capital
$382.02M
Debt to equity
0.02
Current ratio
10.15
Quick ratio
9.89
Net debt/EBITDA
0.46
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-60.8%
Return on equity
-83%
Return on invested capital
-73.7%
Return on capital employed
-54%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SMMT stock price
How has the Summit Therapeutics stock price performed over time
Intraday
-36.06%
1 week
-4.65%
1 month
15.93%
1 year
560.99%
YTD
31.49%
QTD
21.64%
Financial performance
How have Summit Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$226M
Net income
-$221.32M
Gross margin
N/A
Net margin
N/A
The net income has soared by 64% YoY but it has contracted by 13% from the previous quarter
The operating income has soared by 63% YoY but it has contracted by 15% from the previous quarter
Growth
What is Summit Therapeutics's growth rate over time
Valuation
What is Summit Therapeutics stock price valuation
P/E
N/A
P/B
44.51
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 100% YoY
The P/B is 197% above the 5-year quarterly average of 15.0 and 9% above the last 4 quarters average of 41.0
SMMT's equity is down by 11% since the previous quarter
Efficiency
How efficient is Summit Therapeutics business performance
The company's return on equity has surged by 85% YoY and by 20% QoQ
The ROA has soared by 77% YoY and by 5% from the previous quarter
SMMT's return on invested capital has surged by 70% year-on-year but it is down by 10% since the previous quarter
Dividends
What is SMMT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SMMT.
Financial health
How did Summit Therapeutics financials performed over time
SMMT's total assets has soared by 115% YoY but it is down by 13% from the previous quarter
The total liabilities has dropped by 63% year-on-year and by 28% since the previous quarter
The debt is 98% smaller than the equity
Summit Therapeutics's debt to equity has plunged by 99% YoY and by 71% from the previous quarter
The debt has dropped by 93% year-on-year and by 78% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.